Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 578,571
  • Shares Outstanding, K 149,695
  • Annual Sales, $ 53,450 K
  • Annual Income, $ -168,840 K
  • 60-Month Beta 2.34
  • Price/Sales 10.82
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.05
  • Number of Estimates 7
  • High Estimate -0.03
  • Low Estimate -0.08
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +82.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.07 +25.90%
on 11/13/19
4.10 -5.73%
on 12/05/19
+0.57 (+17.12%)
since 11/06/19
3-Month
2.22 +73.71%
on 10/11/19
4.10 -5.73%
on 12/05/19
+1.03 (+36.09%)
since 09/06/19
52-Week
1.76 +119.60%
on 05/31/19
6.13 -36.90%
on 02/25/19
-1.60 (-29.34%)
since 12/06/18

Most Recent Stories

More News
ImmunoGen (IMGN) Up 51.7% Since Last Earnings Report: Can It Continue?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMGN : 3.87 (-0.64%)
ImmunoGen Announces Webcast of Presentation at the Piper Jaffray 31st Annual Healthcare Conference

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at...

IMGN : 3.87 (-0.64%)
Immunogen Inc Set to Possibly Rebound After Yesterday's Selloff of 3.98%

Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $3.25 to a high of $3.42. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $3.26...

IMGN : 3.87 (-0.64%)
Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs

Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.

AZN : 47.68 (+0.13%)
GSK : 45.51 (+0.66%)
RHHBY : 38.5700 (+0.36%)
IMGN : 3.87 (-0.64%)
Watch for Immunogen Inc to Potentially Pullback After Gaining 51.30% Yesterday

Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $3.36 to a high of $3.76. Yesterday, the shares gained 51.3%, which took the trading range above the 3-day high of $3.66...

IMGN : 3.87 (-0.64%)
ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting

--Preclinical Data for IMGN632 in Combination with Azacitidine and Venetoclax Support Clinical Evaluation of Doublets and Triplet in AML

IMGN : 3.87 (-0.64%)
ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally

ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end....

ABBV : 86.98 (+0.30%)
CELG : 108.24 (+0.10%)
JAZZ : 149.46 (+0.92%)
IMGN : 3.87 (-0.64%)
Company News for Nov 4, 2019

Companies In The News Are: MOBL, GOOGL, IMGN, HMSY

GOOGL : 1,339.39 (+0.94%)
MOBL : 4.63 (-0.11%)
HMSY : 29.50 (+0.99%)
IMGN : 3.87 (-0.64%)
ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 21.05% and 45.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

IMGN : 3.87 (-0.64%)
ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results

--Phase 3 MIRASOL Trial for Mirvetuximab in Ovarian Cancer on Track to Start by Year-End

IMGN : 3.87 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade IMGN with:

Business Summary

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended...

See More

Key Turning Points

2nd Resistance Point 4.09
1st Resistance Point 3.98
Last Price 3.87
1st Support Level 3.79
2nd Support Level 3.72

See More

52-Week High 6.13
Fibonacci 61.8% 4.46
Fibonacci 50% 3.94
Last Price 3.87
Fibonacci 38.2% 3.43
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar